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A fundamental aspect of epithelial homeostasis is the
dependence on specific growth factors for cell
survival, yet the underlying mechanisms remain
obscure. We found an ‘‘inverse’’ mode of receptor
tyrosine kinase signaling that directly links ErbB
receptor inactivation to the induction of apoptosis.
Upon ligand deprivation Mig6 dissociates from the
ErbB receptor and binds to and activates the tyrosine
kinase c-Abl to trigger p73-dependent apoptosis in
mammary epithelial cells. Deletion of Errfi1 (encod-
ing Mig6) and inhibition or RNAi silencing of c-Abl
causes impaired apoptosis and luminal filling of
mammary ducts. Mig6 activates c-Abl by binding to
the kinase domain, which is prevented in the pres-
ence of epidermal growth factor (EGF) by Src family
kinase-mediated phosphorylation on c-Abl-Tyr488.
These results reveal a receptor-proximal switch
mechanism by which Mig6 actively senses EGF
deprivation to directly activate proapoptotic c-Abl.
Our findings challenge the common belief that depri-
vation of growth factors induces apoptosis passively
by lack of mitogenic signaling.
INTRODUCTION
Most epithelial cell types rely on signaling controlled by
members of the four epidermal growth factor (EGF) receptor-
tyrosine kinases, EGFR and ErbB2-4, to regulate cellular func-
tions as diverse as proliferation, survival, cell differentiation,
and motility (Avraham and Yarden, 2011; Linggi and Carpenter,
2006). Conversely, their deregulation disrupts normal tissue
homeostasis and contributes to the formation of a vast propor-
tion of epithelial cancers. Ligand binding causes ErbB receptorDevelopmenhomo- or heterodimerization, which leads to allosteric induction
of their intrinsic tyrosine kinase activity and subsequent auto- or
transphosphorylation (Jura et al., 2009; Red Brewer et al., 2009;
Scheving et al., 2006). Furthermore, compelling evidence indi-
cate that the ErbB receptors synergize with the membrane
bound nonreceptor tyrosine kinase Src for full receptor activa-
tion. Src associates with the ErbB receptors via its kinase
domain to further phosphorylate them on multiple important
tyrosine residues (Tice et al., 1999; Kim et al., 2005; Sato et al.,
1995).
The ErbB receptors are under tight spatiotemporal control, in
part through negative feedback loops to ensure correct signaling
outcome (Avraham and Yarden, 2011). The multiadaptor protein
Mig6, also called RALT, is a negative feedback regulator of
the ErbB receptors that acts by directly binding to the active
receptor kinase domain thereby interfering with the formation
of the activating dimer interface (Zhang et al., 2007a). In addition
Mig6 plays a role in endosomal targeting of the receptors for
degradation (Fiorentino et al., 2000; Frosi et al., 2010; Jura
et al., 2009; Ying et al., 2010; Zhang et al., 2007a). The physiolog-
ical importance of Mig6 is evident by recent findings that Errfi1
(encoding Mig6) null mice exhibit sustained ErbB signaling and
develop hyperplasia and tumors in various tissues (Ferby et al.,
2006; Zhang et al., 2007b). Furthermore, Mig6 is frequently
downregulated in various types of human cancers, consistent
with an important tumor suppressive function for Mig6 (Ama-
tschek et al., 2004; Ferby et al., 2006; Reschke et al., 2010).
Individual cells express numerous members of the receptor
tyrosine kinases superfamily many of which activate the same
canonical mitogenic signaling pathways, yet cells depend on
specific growth factors for their survival. Here, we identify
a Mig6-controlled receptor-proximal switch mechanism that
directly links ErbB receptor inactivation to the activation of the
proapoptotic c-Abl, thereby establishing cellular dependence
on EGF in mammary epithelial cells. Interfering with Mig6 func-
tion by gene targeting or loss of c-Abl function leads to disrupted
mammary morphogenesis characterized by ductal luminal filling
due to impaired cell death.tal Cell 23, 547–559, September 11, 2012 ª2012 Elsevier Inc. 547
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Figure 1. Deletion of Errfi1 Leads to
Impaired Cell Death and Propagation of
Luminal Epithelial Cells during Mammary
Morphogenesis
(A) Mammary glands from BrdU-injected 6-week-
old Errfi1/ or wild-type littermate control mice
were either subjected to whole-mount carmine
staining (upper panels) or terminal end buds and
mammary ducts were subjected to immunostain-
ing for cleaved caspase 3 (Ccasp-3), or BrdU as
indicated. Mammary ducts from a 10-week-old
Errfi1/ or wild-type littermate control mice were
stained for keratin-14 (K14) or keratin-18 (K18) as
indicated.
(B) pMECs were isolated from 14- to 15-week-old
Errfi1/ (KO) or wild-type (WT) littermate mice
and subjected to flow cytometry with antibodies
against indicated proteins. The number of
CD24high mature luminal cells (circled red) and
CD24low basal/myoepithelial cells (circled gray) are
represented in the inlayed graphs.
(C) Quantification of cleaved caspase 3+ cells in
terminal end buds of KO or WT littermate
mammary glands, and % BrdU+ cells in TEBs and
ducts analyzing longitudinal sections from mice
aged 6–8weeks. Data were analyzed by two-tailed
unpaired Student’s t test (p = 0.0023, denoted
three asterisks), while error bars represent SEM.
n = 14 (Ccasp-3) and n = 12 (BrdU) independent
TEBs from five mice (WT), and n = 9 (Ccasp-3) and
n = 9 (BrdU) TEBs from five mice (KO); and for
ductal BrdU incorporation: n = 15 (WT) and n = 12
(KO) ducts from six and five mice, respectively.
(D) Epithelial cell autonomous function of Mig6.
Cleared mammary fat pad transplantation of
pMECs isolated fromWT or KO littermates intoWT
hosts and analysis of mammary outgrowths by
carmine staining or mammary ducts by H&E or
immunostaining for K14 and K18 as indicated.
(E) The degree of filling of primary ducts was
quantified as the ratio of higher intensity areas
(orange) of carmine staining over the total
ductal area (middle panels show representative
sections). Dots in the left hand graph represent the
mean high intensity area/total ductal area per
mouse. The number of branchpoints per gland
was determined comparing glands from Errfi1/
(KO) mice or littermate wild-type (WT) controls
plotted individually (n = 9 for WT and KO mice;
n = 6 for WT and KO transplants. Failed transplant
outgrowths were excluded (in parenthesis). Data
were analyzed by two-tailed unpaired Student’s
t test. The black bar indicates the mean while red
bars represent SEM. Scale bars: 1 mm (whole
mounts) and 25 mm (H&E and immunofluores-
cence images).
See also Figure S1.
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Mig6 Activates c-Abl upon EGFR InactivationRESULTS
Loss of Mig6 Leads to Impaired Epithelial Cell Death
during Mammary Ductal Morphogenesis
To explore the mechanism by which Mig6 regulates epithelial
morphogenesis, we examined the development of themammary
gland in the Errfi1 null mice. We found that loss of Mig6 leads to
disruption of ductal morphogenesis of the mammary gland char-548 Developmental Cell 23, 547–559, September 11, 2012 ª2012 Elsacterized by filling of terminal end buds andmammary ducts and
a 5-fold decrease in ductal branching (Figures 1A and 1E; Fig-
ure S1A available online). Histological analysis of cross sections
of the mammary ducts from pubertal and adult mammary glands
revealed a multilayered, epithelium (Figure 1A; Figure S1A) with
widespread luminal filling (Figure 1E) in the Errfi1/ mice. The
expanded cell layers constitute luminal epithelial cells rather
than basal/myoepithelial cells, as shown by immunostaining forevier Inc.
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Mig6 Activates c-Abl upon EGFR Inactivationthe differentiation basal/myoepithelial marker keratin-14, and
markers for luminal cells: keratin-18 (Figure 1A), E-cadherin,
and GATA-3 (Figure S1A). To confirm the selective propagation
of luminal over basal/myoepithelial cells, we performed flow
cytometrical analysis of freshly isolated Errfi1/ and wild-type
mammary cells. The Errfi1/ primary mammary epithelial cells
(pMECs) showed a 3-fold increase in the CD24high/integrin-
b1low mature luminal cell population, relative to the CD24low/
integrin-b1high basal/myoepithelial cell population (Figure 1B).
Bim (Bcl-2 interacting mediator of cell death)-dependent
apoptosis has previously been shown to play a crucial role in
the process of lumen formation of the mammary gland (Mailleux
et al., 2007), suggesting that the luminal filling in the Errfi1/
mice may be due to impaired cell death. In agreement, invading
terminal end buds (TEBs) of pubertal Errfi1/ mammary glands
showed a 7-fold decrease in cell death as compared to wild-type
littermates, as determined by quantification of cleaved caspase-
3 positive cells (Figure 1C). In contrast, cell proliferation (incorpo-
ration of bromodeoxyuridine [BrdU]) was not affected neither in
TEBs nor ducts by loss of Errfi1 (Figures 1A and 1C). In addition,
Errfi1/ pMECs proliferated at the same rate as wild-type
control cells in vitro (Figure S1B). Together, these results show
that loss ofMig6 leads to selective propagation of luminal epithe-
lial cells due to impaired cell death rather than increased cell
proliferation.
Mig6 Is Required Cell Autonomously in Epithelia
for Luminal Clearance
Ductal morphogenesis of the mammary glands involves both
epithelial cell autonomous, micro-environmental and paracrine
factors. Notably, Mig6 is also expressed in fibroblasts
surrounding the mammary ducts (data not shown). To assess
the epithelial-specific requirement for Mig6 in mammary mor-
phogenesis, we transplanted pMECs isolated from Errfi1/ or
wild-type littermate mice into cleared fat pads of wild-type
recipient mice and characterized reconstituted glands by
whole-mount carmine staining and IHC on ductal cross sections
(Figure 1D). Errfi1/ glands in a wild-type background recapitu-
lated the ductal luminal filling phenotype, as quantified by optical
density analysis of carmine stained primary ducts (Figure 1E),
demonstrating that Mig6 regulates luminal clearance in a cell
autonomous fashion in the epithelia during mammary morpho-
genesis. Determination of the number of branchpoints in the
full Errfi1 null mice as compared with wild-type controls revealed
a 5.5-fold decrease in ductal branching, while there was greater
variability and no statistically significant difference in branching
between wild-type and Errfi1 knockout glands reconstituted in
wild-type hosts (Figure 1E). These results indicate a possible
involvement of Mig6 in the microenvironment for branching
morphogenesis, while it has a cell-autonomous function in
epithelia to mediate luminal clearance. Further studies will be
required to address the role of Mig6 in branchingmorphogenesis
To explore the cellular mechanism by which Mig6 regulates
mammary epithelial cell death, we first characterized Errfi1/
pMECs cultured in vitro. These cells exhibit normal cell prolifer-
ation rate as shown by the MTT reduction assay (Figure S1B).
In addition, Errfi1/ pMECs shown normal cellular morphology
as indicated by phase contrast microscopy (Figure S2A).
Epithelial cell differentiation also appeared unaffected by lossDevelopmenof Mig6 as shown by immunoblotting against differentiation
markers keratin-14, -18, E-Cadherin, b-catenin, Musashi, and
GATA-3 (Figure S2B).
pMECs require an EGF ligand for survival and removal of EGF
from otherwise growth factor supplementedmedia triggers rapid
cell death in wild-type pMECs (Figure 2A). Errfi1/ cells,
however, were resistant to cell death induced by EGFR inactiva-
tion, as determined by cleavage of caspases-3 and -9, induction
of Bim (Figure 2A) or cell membrane permeability (Figure 2B). We
asked whether Mig6 has a more general role in promoting cell
death. This was not the case since neither anoikis nor DNA
damage (adriamycin)-induced cell death was affected by loss
of Mig6 (Figures S2C and S2D).
We then addressed whether luminal cells are subjected to
inactivation of ErbB signaling in vivo by examining cross sections
of TEBs for immunoreactivity against active ErbB2 using a phos-
phospecific antibody. While active ErbB2 was readily detectable
in the basal cell layers of the TEB as well as ductal luminal cells,
cells in the interior of TEBs show only limited or undetectable
levels of phospho-ErbB2 staining (Figure 2C). Inactivation of
ErbB receptors may therefore contribute to cell death and
luminal clearance of TEBs.
Mig6 Regulates Mammary Epithelial Cell Death
Independent of Its Role as a Negative Regulator
of ErbB Signaling
Given the known function of Mig6 as a negative regulator of the
ErbB receptors (Ferby et al., 2006; Frosi et al., 2010; Zhang et al.,
2007b) we asked whether gain of basal ErbB kinase activity
underlies the acquired EGF-independent survival of Errfi1
mutant cells. However, western analysis of Errfi1/ and wild-
type pMECs did not show an increase in EGFR activation or
mitogenic signaling via Erk1/2, Akt, and GAB2 neither in the
presence nor absence of EGF (Figures S2B and S2E). Further-
more, treatment of pMECs with the specific ErbB inhibitors
AG825 (ErbB2), gefitinib (EGFR), or lapatinib (EGFR and ErbB2)
prior to EGF deprivation failed to rescue the EGF-independent
survival of Errfi1/ cells (Figures 2D and S2F). These results
suggest that Mig6 regulates mammary epithelial cell death inde-
pendent of its role as a negative regulator of the ErbB receptors.
EGFR Inactivation Leads to Mig6-Dependent Activation
of Abl and Induction of Cell Death
In order to identify the putative survival or apoptotic pathway
regulated by Mig6 we used specific inhibitors against kinases
known to play a role in survival signaling downstream of the
ErbB receptors including MEK, PI-3K, the Src family of kinases,
c-Met, and c-Abl and analyzed their effect on apoptosis trig-
gered by EGF-deprivation in wild-type and Errfi1/ pMECs
(Figures S2F and S2G). While all inhibitors failed to rescue the
Mig6-dependent apoptotic response, treatment with the specific
second generation c-Abl inhibitor nilotinib (Tasigna) (Hantschel
et al., 2008), prevented cell death in response to EGFR inactiva-
tion (Figure 2D). To confirmwhether c-Abl is the relevant target of
nilotinib, we performed RNAi-mediated knockdown of c-Abl in
pMECs using two nonoverlapping shRNAs that similarly reduced
cell death induced by EGF deprivation (Figures 2E). These results
show that c-Abl is required for cell death induced by EGF
deprivation.tal Cell 23, 547–559, September 11, 2012 ª2012 Elsevier Inc. 549
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Figure 2. c-Abl Is Activated upon EGF Deprivation in a Mig6-Dependent Manner and Required for Apoptosis
(A) Errfi1/ or wild-type pMECswere cultured in the presence (+) or absence () of 10 ng/ml EGF for indicated times and cell lysates subjected to immunoblotting
as indicated.
(B) Trypan blue cell viability assay on Errfi1/ or wild-type pMECs cultured in the presence (+) or absence () of 10 ng/ml EGF for 8 hr. The%of cells taking up the
dye is indicated (n = 3 independent experiments; ***p = 0.00015).
(C) Longitudinal sections of a TEB or duct from wild-type (WT) or Errfi1/ (KO) mice (5 and 6 weeks of age, respectively) subjected to immunostaining for active
phospho-Y877-ErbB2 and counterstained with DAPI. Note the absence of active ErbB2 in the interior luminal cell layers in the wild-type TEB or Errfi1/ duct.
Representative images of eight analyzed TEBs and ducts from a 6-week-old mouse.
(D) Errfi1/ (KO) or littermate wild-type pMECs (WT) were deprived of EGF for 6 hr in the absence () or presence (+) of 1 mM lapatinib, 1 mM nilotinib, prior to
western analysis for indicated proteins. The right panels constitute a separate independent experiment. Note that inhibition of c-Abl disrupts EGF-deprivation
induced cell death, while inhibition of EGFR and ErbB2 fails to rescue the cell death defect of the KO pMECs.
(E) pMECs subjected to shRNAi-mediated knock-down of c-Abl using two independent constructs were deprived of EGF for 6 hr and cell lysates immunoblotted
for indicated proteins.
(F and G) pMECs from Errfi1/ or littermate wild-type mice were cultured in the presence or absence of EGF for 2 hr prior to harvest, followed by immuno-
precipitation of c-Abl and immunoblotting for total phospho-tyrosine (F) or tyrosine 245 (G, independent experiment), indicating that c-Abl is rapidly activated
upon EGF withdrawal in a Mig6-dependent manner. The numbers indicate fold increase in intensity as determined by densitometric analysis.
(H and H0 ) pMECs from KO or littermate WT mice were cultured in the presence or absence of EGF for 2 hr prior to harvest, followed by immunoprecipitation of
c-Abl and an in vitro kinase assay using a specific Abl substrate peptide (Abltide) as a substrate. (H0 ) Quantification of kinase activity as fold change over the EGF
stimulated WT samples (n = 4, ***p = 0.00017).
See also Figures S2 and S3). Indicated p values were determined by two-tailed unpaired Student’s t test, while the error bars represent SEM.
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Mig6 Activates c-Abl upon EGFR InactivationSubstantial evidence from cultured cells support a role for
c-Abl in promoting cell death in response to different cellular
stresses, including DNA damage, reactive oxygen species, ER
stress or by the proapototic cytokine TNFa (Agami et al., 1999;
Chau et al., 2004; Gong et al., 1999; Ito et al., 2001; Noren
et al., 2006; Sun et al., 2000), although in vivo evidence remains
limited primarily due to neonatal lethality of Abl knockout mice
(Tybulewiczet al., 1991). To investigatewhetherc-Abl is activated
upon EGF deprivation, wild-type and Errfi1/ pMECs were
cultured with or without EGF, followed by examination of c-Abl
phosphorylation on either all tyrosine residues (pY) or the regula-550 Developmental Cell 23, 547–559, September 11, 2012 ª2012 Elstory Y245 (pY245) alone by western analysis of immunoprecipi-
tatedAbl (Figures2Fand2G).Strikingly, tyrosinephosphorylation
of c-Abl was readily detectable already after 2 hr following EGF
withdrawal prior to caspase-3 cleavage (Figures 2F and 2G)
and remained phosphorylated for up to 12 hr (data not shown).
In agreement, immunoprecipitated c-Abl showed a 3.6-fold
increase in kinase activity upon EGF withdrawal (Figures 2H
and 2H0). On the contrary, phosphorylation and activation of
c-Ablwerenot induced inErrfi1/pMECs.Taken together, these
results show that Mig6-dependent activation of c-Abl is required
formammary epithelial cell death in response to EGFdeprivation.evier Inc.
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Figure 3. Mig6 Interacts with and Activates c-Abl
(A) c-Abl or Mig6 were immunopurified from HEK293T cells ectopically coexpressing Mig6 and wild-type (WT), catalytically inactive (KD), or constitutively active
(PP) forms of c-Abl and examined by immunoblotting as indicated.
(B and C) Immunopurification of endogenous Mig6 from pMECs cultured in the presence or absence of EGF for 2 hr and examined for interaction with c-Abl (B) or
EGFR (C).
(D) Immunoprecipitated EGFR from HEK293T cells ectopically coexpressing EGFR and Mig6 or mutant forms of Mig6 lacking the AH1 domain (deletion
aa 328–361) or the Grb2 binding site (PP319/20AA) and examined by immunoblotting as indicated.
(E) Immunoprecipitation of c-Abl coexpressed with Mig6 and EGFR in HEK293T cells followed by immunoblotting as indicated.
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To explore the mechanism by which Mig6 contributes to c-Abl
activation, we first addressed whether the two proteins
physically interact. Indeed, ectopically expressedMig6 coimmu-
noprecipitated with wild-type (WT), kinase-dead (KD), and
constitutively active (PP) forms of c-Abl (Figure 3A). Strikingly,
Mig6 triggered activation of c-Abl as shown by the strong
increase in autophosphorylation or phosphorylation of Y412 of
Abl (Figure 3A, upper four panels). Furthermore, Mig6 was phos-
phorylated upon Abl overexpression indicating that it is also
a substrate of c-Abl (Figure 3A, middle three panels). We then
asked whether the Abl/Mig6 interaction could be detected at
the endogenous level in pMECs and found that Mig6 coimmuno-
precipitated with c-Abl both in the presence and absence of
EGF, in a manner that could be partially prevented by nilotinib
(Figure 3B). In addition, we incubated bacterially produced
Mig6 with immunopurified Abl, followed by immunoprecipitation
of c-Abl and western analysis for binding of Mig6 and phosphor-
ylation of c-Abl (Figure S2H). Although Abl bound effectively to
recombinant Mig6, only a modest 2.2-fold activation of Abl in
the presence of Mig6 was observed, raising the possibility that
additional proteins may be required for full Mig6-induced activa-
tion (Figure S3H). Taken together, these results reveal that Mig6
binds directly to and activates c-Abl.
We next investigated the ability of EGFR to coimmunoprecipi-
tate with Mig6 and found that the two proteins bind in the pres-
ence but not absence of EGF (Figure 3C). Ectopically expressed
Mig6 or mutant Mig6 deficient for Grb2 binding (PP319/20AA)
coimmunoprecipitated with EGFR and inhibited EGFR auto-
phosphorylation, as shown by western analysis (Figure 2D). On
the contrary, Mig6 lacking the short EGFR interaction motif
homologous to Ack1, the AH1 domain (Frosi et al., 2010; ZhangDevelopmenet al., 2007a), failed to bind to and inhibit EGFR (Figure 2D).
These results are consistent with themodel proposed by Kuriyan
and coworkers (Zhang et al., 2007a) that Mig6 binds to the
activating EGFR kinase domain interface, thereby attenuating
autoactivation, and that Mig6 dissociates from EGFR upon
receptor inactivation.
To address whether Mig6-induced activation of Abl could be
regulated by EGFR activity, we ectopically expressed Abl with
Mig6, in the presence or absence of active EGFR and analyzed
Abl activation. Overexpression of active EGFR effectively pre-
vented Mig6 binding to and activation of Abl (Figure 3E). This is
consistent with a switch-like mechanism, whereby Mig6 either
interacts with and attenuates EGFR activity or, upon inactiva-
tion/absence of EGFR, activates c-Abl.
To further characterize the molecular interaction between
Mig6 and c-Abl, we ectopically expressed a series of deletion
mutants of c-Abl and assessed their ability to coimmunoprecipi-
tate withMig6. Contrary to previously described Abl interactions,
Mig6 does not bind to the SH3, SH2 domain or the last exon
region (outlined in Figure S3A), but interacts with the inactive
(kinase-dead) c-Abl kinase domain and less efficiently with the
wild-type kinase domain (Figure S3B). In agreement, Mig6 was
still able to interact with c-Abl point mutants that disrupt phos-
photyrosine- or PxxP-ligand binding to the SH2 (R171L) or the
SH3 (W118A) domains, respectively (Figure S3C).
Mig6 Activates Abl by Interacting with the Kinase
Domain via Its Conserved ErbB Binding Region
Given the unique ability of Mig6 to interact directly with and acti-
vate the c-Abl kinase domain, we asked whether the interaction
site is similar to that of Mig6 on the EGFR kinase domain, which
was revealed by the crystal structure of the EGFR kinase domaintal Cell 23, 547–559, September 11, 2012 ª2012 Elsevier Inc. 551
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(A) Coimmunopurification of ectopically expressed c-Abl and full length (WT) Mig6 or fragments of HA-tagged Mig6 constituting either the minimal ErbB inter-
action aa 335–365 (Ack homology region 1, AH1) or the complete Ack homology region aa 314–412 (AH1+2).
(B) Outline of the minimal region of Mig6 required for Abl activation with point mutations generated.
(C) Molecular modeling of the predicted c-Abl/Mig6 interface based on the structural similarity with EGFR bound toMig6 (EGFR/Mig6: PDB 2RF9 and c-Abl: PDB
1OPK). View of the c-Abl kinase domain (light blue) andMig6 (red) with residues F352 and Y358 (highlighted red) known to contribute to theMig6/EGFR interface.
The regulatory helix I0 of c-Abl is shown in its inactive closed conformation (blue, PDB 1OPK) or active open conformation (yellow, PDB 1OPJ). Note the apparent
clash between Mig6 and the inactive but not active I0 helix conformation. c-Abl residues predicted to participate in the interaction with Mig6 that were mutated in
d are highlighted yellow.
(D) Coimmunopurification of ectopically expressedMig6with mutant forms of c-Abl with indicated point mutations, implicating the predicted C-lobe interface is in
the activation of Abl by Mig6.
(E) Identification of the Abl phosphorylation sites onMig6. Immunopurification of ectopically expressedwild-type or Y394/395Fmutants ofMig6 and constitutively
active c-Abl-PP.
(F) Coimmunopurification of ectopically expressed HA-tagged inactive c-Abl kinase domains with indicated C-lobe mutation withWT or mutated forms of Mig6 in
the presence or absence of nilotinib (2 mM).
See also Figure S3.
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2007a). We found that ectopic expression of a short extended
peptide containing the EGFR-binding-AH1 domain (AH1+2),
although not AH1 alone, was sufficient to trigger c-Abl activation
(Figures 4A and 4B). This points toward a similar interaction
interface for Mig6/c-Abl and Mig6/EGFR. Superimposition of
structures of the EGFR and c-Abl kinase domains revealed
a strong conservation in the Mig6 binding region of EGFR and
the corresponding region of c-Abl. In total, six of eight critical
Mig6-contact residues are conserved between Abl and EGFR
and display a similar spatial orientation (Figures S3D and S3E).
To address whether Mig6 interacts with c-Abl as predicted
based on the analogy with Mig6 binding to the EGFR, we gener-
ated point mutants of predicted contact residues on the C-lobe
of the Abl kinase domain (schematically outlined in Figure 4C)
and assessed their ability to interact with and become activated
by Mig6 (Figure 4D). All these point mutations prevented Mig6-
mediated activation of Abl, indicating the involvement of the
Abl kinase domain C-lobe in the functional interaction with
Mig6 (Figure 4D). These mutations did not, however, prevent552 Developmental Cell 23, 547–559, September 11, 2012 ª2012 ElsMig6 from interacting with Abl implying the existence of another
binding site.
Since Mig6 preferentially interacts with the inactive c-Abl
kinase domain, rather than the active kinase that phosphorylates
Mig6 (Figure S3B), we speculated that Mig6 additionally binds
to the catalytic site of Abl, leading to Mig6 phosphorylation
and dissociation from the active site. To identify the region of
Mig6 that interacts with the Abl catalytic site, we first mapped
the Abl phosphorylation sites on Mig6 to Y394/5 within the
Ack1 homology region (outlined in Figure 2B). Mutation of
these phosphorylation sites (Y394/5) to alanine eliminated Abl-
induced phosphorylation of Mig6 (Figure 4E). The Y394/5F
mutations partially abolished Mig6 binding to the inactive Abl
kinase domain suggesting that Mig6 binds to the Abl catalytic
site via the Ack1 homology domain (Figure 4F). As predicted,
nilotinib, which binds the Abl catalytic site causing major
misplacement of the activation loop also reduced the Mig6-Abl
interaction (Figure 4F). Residual binding of Mig6 to the Abl cata-
lytic site, that was observed in the presence of nilotinib, was
abolished by mutations predicted to disrupt the C-lobe bindingevier Inc.
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Figure 5. Phosphorylation of Abl on Y488 by
Src-Kinases Regulates Mig6-Induced Acti-
vation of Abl
(A) Coimmunopurification of ectopically expressed
Mig6 with wild-type (WT), Y488E, or Y488F forms
of c-Abl in HEK239T cells followed by western
analysis as indicated. Note that the phosphomimic
Y488E and partially the Y488F mutation disrupts
the ability of Mig6 to activate c-Abl.
(B) In vitro kinase assay with recombinant active
c-Src or EGFR with wild-type (WT), Y488E or
Y488F mutant forms of the inactive catalytic
domain of c-Abl immunopurified from over-
expressing HEK293T cells.
(C) Immunoprecipitation of WT or Y488F mutant c-
Abl coexpressed with Mig6 and active c-Src, fol-
lowed by western analysis as indicated.
(D) Western analysis of endogenous phosphory-
lation of Abl on Y488 in pMECs cultured in the
presence or absence of EGF for 2 hr prior to cell
harvest. Values denote relative intensities of p488
bands, normalized against total c-Abl levels.
(E) Western analysis of endogenous phosphory-
lation of Abl on Y488 in control wild-type MEFs or
MEFs lacking Src-family members. Values denote
relative intensities of p488 bands, normalized
against total c-Abl levels.
(F) Immunopurification of c-Abl coexpressed with
Mig6 and EGFR with or without 0.8 mM of the Src
inhibitor PP2 and western analysis as indicated.
Note the Src-dependent inhibition of Mig6-
induced Abl activation by EGFR overexpression.
(G) Western analysis of immunoprecipitated
endogenous c-Abl for Y phosphorylation in pMEFs
cultured in the presence of EGF, treated with 0.4
or 0.8 mM PP2 for 2 hr. Values denote relative
intensities of pY bands, normalized against total
immunoprecipitated c-Abl levels, as determined
by densitometry.
(H) Induction of cell death by Mig6/Abl but not Src/
Abl. Ectopic expression of Abl with or withoutMig6
or Src in pMEFs for 16 hr, followed by western
analysis as indicated. Graph shows cell death
determined as% of cells taking up the viability dye
trypan blue (n = 3).
(I) siRNA-mediated silencing of p73 followed by
ectopic coexpression of Abl andMig6 in pMEFs for
16 hr, and western analysis as indicated. Graph shows cell death determined as % of cells taking up the viability dye trypan blue (n = 3).
(J) C-Abl immunofluorescence in WT or Errfi1 KO pMECs cultured in absence of EGF for 2 hr. Note the reduced nuclear staining of c-Abl in the absence of Mig6.
Images are representative of three independent experiments.
Indicated p values were determined by two-tailed unpaired Student’s t test, while the error bars represent SEM.
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Mig6 Activates c-Abl upon EGFR Inactivationinterface: Abl (Y488E) and Mig6 (F352A/Y358A) (Figure 4F).
Collectively, these results show that the Ack1 homology region
of Mig6 binds both to the catalytic site and the C-lobe of Abl.
Interestingly, molecular modeling indicates that the autoinhibited
c-Abl conformation is not compatible with Mig6 binding, as there
are clashes with Mig6 and the bent I0 helix in the Abl kinase
domain (labeled blue in Figure 4C).
Src-Family Kinases Negatively Regulate Mig6-Mediated
Abl Activation
We noted that Abl-Y488, which is a known phosphorylation site
with yet unknown function (Hantschel and Superti-Furga, 2004;
Salomon et al., 2003), faces the predicted Mig6 interaction inter-Developmenface (highlighted in Figure 4C). This raises the possibility that
phosphorylation of this site may regulate Mig6-induced activa-
tion. The Y488E mutation that mimics the phosphorylated
tyrosine residue abolished the ability of Mig6 to activate c-Abl
(Figure 5A), while the phenylalanine mutation (Y488F) led to
decreased Mig6-mediated c-Abl activation (Figure 5A). We
then asked whether either EGFR or c-Src, known to be recruited
to and contribute to full activation of the ErbB receptors (Tice
et al., 1999; Kim et al., 2005; Sato et al., 1995) could be respon-
sible for phosphorylating c-Abl on Y488 and hence negatively
regulate the activation of c-Abl by Mig6. Indeed, recombinant
active c-Src but not EGFR was able to phosphorylate the c-Abl
catalytic domain (Figure 5B). The Y488E/F mutations largelytal Cell 23, 547–559, September 11, 2012 ª2012 Elsevier Inc. 553
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Figure 6. Abl Inhibition Impairs Luminal Cell
Death and Cause TEB Filling
(A) Immunostaining of TEBs for proliferating (BrdU-
positive), cleaved caspase 3 (Ccasp-3) positive
cells, or epithelial markers keratin 14 (K14) or
keratin 18 (K18) of mice treated with nilotinib or
vehicle (representative of three independent
experiments). Scale bars = 20 mm.
(B) Quantification of cleaved caspase 3 positive
cells in TEBs of mock or nilotinib-injected
mammary glands, n = 5 TEBs each sample group
from three independent experiments.
(C–D0) Whole-mount carmine staining of mammary
glands from mock- or nilotinib-injected littermate
mice. (C) The dotted line indicates the estimated
position of the TEBs when treatment was initiated.
Note filling of TEBs and reduced outgrowth of the
secondary side branches upon nilotinib treatment.
Scale bars = 500 mm. (D) The degree of filling of
TEBs was quantified as the ratio of higher intensity
areas of carmine staining over the total TEB area
(as outlined, D0).
(E) Quantification of degree of TEB filling in nilo-
tinib-treated mice, n = 16 (nilotinib) and 12 (mock).
In (B) and (E), data were analyzed by two-
tailed unpaired Student’s t test while error bars
represent SEM.
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Mig6 Activates c-Abl upon EGFR Inactivationprevented Abl phosphorylation by Src indicating that it is a major
Src phosphorylation site (Figure 5B). This was further confirmed
using a phosphospecific antibody generated against pY488.
Ectopically expressed Src, but not Abl itself activated by Mig6,
phosphorylated Abl on Y488 (Figure 5C). Furthermore, we also
found that endogenous c-Abl is phosphorylated on Y488 in the
presence of EGF, while removal of EGF or inhibition of Src-family
kinases with the SU6656 inhibitor lead to an 80% reduction in
Y488 phosphorylation (Figure 5D). To confirm if c-Src and/or
its closely related family members Yes and Fyn are responsible
for phosphorylating endogenous c-Abl, we examined c-Abl-
Y488 phosphorylation in mouse embryo fibroblasts (MEFs)
from Src/Yes/Fyn triple or Yes/Fyn double knockout mice.
Yes/Fyn/MEFs shown a 60% reduction, while Src/Yes/Fyn/
MEFs fully abolish c-Abl-Y488 phosphorylation (Figure 5E). This
indicates that endogenous Src, Yes, and Fyn contribute to phos-
phorylation of Abl-Y488. In addition, the Src family inhibitor PP2
partially restored the ability of Mig6 to activate c-Abl under
conditions when EGFR was overexpressed (Figure 5F). At the
endogenous level, we similarly found that Src inhibition by PP2
treatment lead to a 2.5-fold increase in c-Abl autophosphoryla-
tion (Figure 5G). These results suggest that c-Src kinases,
prevents Mig6-dependent proapoptotic activation of c-Abl in
the presence of EGF by phosphorylating Abl on Y488.
Mig6/Abl but Not Src/Abl Triggers p73-Dependent
Cell Death
We next addressed whether Abl activated byMig6 is sufficient to
trigger cell death by ectopic overexpression in primary MEFs.
Coexpression of Mig6/Abl, but neither alone, nor coexpression
of active Src/Abl, induced efficient cell death in Errfi1/ MEFs,
as evident by immunoblotting for cleavage of caspase-3 or
plasma membrane permeability (Figure 5H). In agreement with
a role for Src-kinases in negatively regulating Mig6/Abl activity,554 Developmental Cell 23, 547–559, September 11, 2012 ª2012 Elsoverexpression of Src, lead to a 69% reduction in Mig6/Abl-
induced cell death (Figure 5H).
To gain insight into the mechanism by which Mig6/Abl triggers
cell death, we asked whether p73, which is an essential proapo-
ptotic target of Abl in response to genotoxic stress, is also
required for Mig6/Abl-induced death. Indeed, siRNA-mediated
silencing of p73 reduced cell death induced by ectopic Mig6/
Abl by 88% (Figure 5I). Nuclear accumulation of Abl has been
reported to be important for its proapoptotic function in
response to genotoxic stress, by allowing Abl to phosphorylate
nuclear p73 (Agami et al., 1999; Chau et al., 2004; Gong et al.,
1999). We therefore examined the cellular localization of Abl in
wild-type and Errfi1/ pMECs by immunofluorescence. Abl
localize in the cytoplasm and nucleus of wild-type pMECs,
both in the absence (Figure 5J) or presence of EGF (data not
shown). Errfi1/ cells exhibited a marked reduction in nuclear
c-Abl as compared with wild-type cells (Figure 5J). This result
raises the possibility that Mig6 is required for targeting Abl to
the nucleus thereby allowing it to activate nuclear p73.
Pharmacological Inhibition or RNAi Silencing of c-Abl
Leads to Impaired Mammary Epithelial Cell Death
and Lumen Formation
To confirm whether c-Abl is required for cell death during
mammary ductal morphogenesis, we treated mice with nilotinib
daily for a week and analyzed the developing mammary glands.
Longitudinal cross sections of TEBs were immunostained using
antibodies against K14, K18, BrdU, and cleaved caspase 3, to
determine the degree of luminal filling, cell death, proliferation,
and differentiation (Figure 6A). Similar to the defects observed
in the Errfi1/ mice, nilotinib treatment resulted in a 82% (p =
0.0045) reduction in the number of cleaved caspase 3 positive
cells (Figures 6A and 6B) and a 2.8-fold (p = 0.0001) increase
in luminal filling of TEBs (Figure 6E). The degree of filling wasevier Inc.
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Figure 7. Silencing of c-Abl Leads to
Impaired Mammary Lumen Formation and
Branching Morphogenesis
(A–C) pMECs were subjected to lentivirus-medi-
ated shRNA silencing of c-Abl and cultured inside
(A and A0) or on top of (B and B0) Matrigel. (A) The
degree of luminal filling of individual acini was
determined in a blind fashion from stacks of phase
contrast and GFP fluorescence images (see A0 for
representative acini). The proportion of spheres
within the indicated subcategories are repre-
sented (n = 3 independent experiments with a total
of 120 control and 118 Abl knockdown (k.d.) acini
analyzed). (B) The number of branches of indi-
vidual spheres cultured on top of Matrigel are
plotted, n = 3 independent experiments with
a total of 83 (ctrl) and 72 (Abl k.d.) acini analyzed.
p = 0.006 for difference in mean number of
branches per ctrl versus acini. (B0) Phase contrast/
GFP images of representative acini. (C) Western
analysis for indicated proteins of pMECs infected
with the nontargeting or c-Abl-targeting shRNAs,
confirming efficient knockdown. p values were
determined by two-tailed unpaired Student’s t test
(A) or Mann-Whitney test (B), while error bars
indicate SEM.
(D) Model illustrating the molecular switch mechanism by which Mig6 senses ErbB receptor inactivation. In the presence of EGF the ErbB-binding region of Mig6
(red) binds to the active ErbB receptors interfering with kinase domain dimer formation (Zhang et al., 2007a). C-Src is recruited to and activated by active ErbB
receptors and phosphorylates c-Abl on Y488, thereby preventing Mig6 from activating c-Abl to induce p73-dependent cell death. Upon ErbB receptor inacti-
vation c-Abl and Mig6 dissociate from the receptor, leading to de-phosphorylation of c-Abl on Y488, which enable Mig6 to activate c-Abl to trigger p73-
dependent cell death.
Developmental Cell
Mig6 Activates c-Abl upon EGFR Inactivationquantified by optical density analysis of carmine stained TEBs
(Figures 6C–6E). Furthermore, nilotinib prevented outgrowth
of the secondary branches but not the larger primary ducts,
raising the possibility that Abl is additionally required for cell
proliferation of secondary but not primary ducts (Figure 6C).
Taken together these results show that nilotinib treatment
phenocopies the impaired cell death and luminal filling observed
in Errfi1/ TEBs.
To confirm that the effect of nilotinib on mammary morpho-
genesis is due to inhibition of c-Abl we subjected pMECs to
lentivirus-mediated shRNA silencing of Abl and cultured the cells
in 3D Matrigel for 12 days and examined the formation of
lumenized acini. This recapitulates aspects of in vivo mammary
morphogenesis such as luminal clearance and ductal branching.
The efficiency of lentiviral shRNA infection and knockdown was
confirmed by green fluorescent protein (GFP) expression and
immunoblotting for Abl (Figures 7A0, 7B0, and 7C). Silencing of
Abl led to a significant (3-fold) increase in filled acini (Figures
7A and A0). Notably, the 14% of Abl knockdown acini that did
form a lumen all exhibited a mosaic pattern of GFP expression
(data not shown), suggesting that cells retaining Abl expression
can support luminal clearance. In addition, pMEC acini cultured
on top of, rather than inside, Matrigel extended branched
structure in 46% of nontargeted control-infected acini, but only
9% of Abl knockdown acini (Figures 7B and B0). RNAi silencing
of c-Abl in the 3D morphogenesis system can therefore recapit-
ulate both the luminal filling and impaired branching phenotypes
observed by nilotinib treatment or loss of Mig6 in mice. Notably,
transplanting the Abl knockdown pMECs back into cleared fat
pads failed to reconstitute the mammary gland, as opposed to
the nontargeted control cells, suggesting that Abl has additionalDevelopmenfunctions early during mammary morphogenesis (Figures S4A
and S4B).
DISCUSSION
We have discovered an ‘‘inverse’’ mode of ErbB receptor
signaling by which Mig6 monitors the activation state of the
receptors to directly trigger apoptosis upon receptor inactiva-
tion. Our findings uncover a bimodal signaling function for
Mig6, whereby in the presence of EGF it attenuates ErbB
receptor dimerization while in the absence of EGF it directly
binds to and activates c-Abl to induce cell death.
Mig6 Is a Sensor of EGFR Activation Status that Creates
Cellular Dependence on EGF
Lack of growth factors is widely thought to cause cell death
passively due to loss of mitogenic and prosurvival canonical
signaling cascades including the Ras/MAPK and PI3K/Akt path-
ways. However, this view is likely to be insufficient as many cell
types are dependent on particular growth factors despite ex-
pressing multiple receptor tyrosine kinases, many of which acti-
vate the same canonical mitogenic signaling cascades. This has
prompted the hypothetical definition of dependence receptors
as those that promote a ‘‘positive’’ mitogenic signal upon ligand
deprivation, but that actively induce a ‘‘negative’’ proapoptotic
signal in the absence of ligand stimulation, such as Ret, Met,
p75NTR, and EphA4 (Bredesen et al., 2004; Mehlen and Brede-
sen, 2004; Furne et al., 2009). One molecular mechanism under-
lying the negative receptor tyrosine kinase (RTK) signaling has in
some cases been proposed to involve receptor cleavage by
caspases that leads to further activation of caspases (Bredesental Cell 23, 547–559, September 11, 2012 ª2012 Elsevier Inc. 555
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Mig6 Activates c-Abl upon EGFR Inactivationet al., 2004; Mehlen and Bredesen, 2004). However, the mecha-
nism by which the caspases are activated by RTK inactivation
in the first place and how the cleaved receptors propagate
apoptosis remains unclear. Here, we show that the proapoptotic
c-Abl kinase is rapidly activated upon ErbB receptor inactivation
to trigger p73-dependent cell death. This involves a unique
receptor-proximal sensory signaling mechanism by which
Mig6 directly activates Abl, prior to the activation of caspase-3
and -9, to trigger apoptosis in the absence of ErbB ligand,
thereby establishing specific cellular dependence on EGF.
A Unique Mechanism of Kinase Activation
The adaptor protein Mig6 is known to specifically interact with
members of the EGFR family of RTKs, in their active but not inac-
tive state, to attenuate sustained kinase activity by disrupting
asymmetric dimer formation. We show that Mig6 also interacts
with the Abl kinase domain via the same interface as EGFR,
but with opposite consequences, i.e., inhibition of EGFR activa-
tion but activation of Abl kinase activity. Notably, the mechanism
by which Mig6 activates Abl is novel since all previously known
substrates and/or activators of Abl bind either to the SH2
or SH3 domains or last exon region of Abl. The activation
mechanism involves binding of Mig6 to the C-lobe of the Abl
kinase domain. Similar to members of the Src family of kinases
c-Abl is maintained in a tight autoinhibited conformation that is
established by intimate intramolecular interactions involving
the kinase domain and the SH2 and SH3 domains (Hantschel
and Superti-Furga, 2004; Superti-Furga and Courtneidge,
1995). Molecular modeling indicates that the autoinhibited
c-Abl conformation is not compatible with Mig6 binding, as
there are clashes with Mig6 and the bent I0 helix in the Abl kinase
domain binding. Our data are consistent with an induced fit
mechanism of activation whereby Mig6 forces the regulatory
helix (I0) to adopt the open conformation leading to a displace-
ment of the SH3-SH2 domain unit and ensuing increase in
tyrosine kinase activity and Abl autophosphorylation. Alterna-
tively Mig6 binding could stabilize the open conformation,
thereby shifting the balance from basal c-Abl activity toward
autoactivation.
We found that Mig6 interacts with the active site of Abl in
a manner that could be regulated by phosphorylation of Mig6
by Abl on Y394/5. Whether endogenous Mig6 binds EGFR and
Abl in the same or separate complexes remains an open ques-
tion. It is, however, plausible that Mig6 interacts simultaneously
with inactive c-Abl via the catalytic site interface and active
EGFR, while binding to the kinase domain C-lobe interfaces on
EGFR or Abl are mutually exclusive.
We further provide evidence for the role of c-Src, and the
closely related family members Yes and Fyn, in controlling the
bimodal function of Mig6; in the presence of EGF c-Src kinases
can phosphorylate Abl on Y488, which faces the predicted Mig6
interface, to prevent Mig6-dependent Abl activation. Intriguingly,
previous studies have shown that c-Src can also contribute to
c-Abl activation by phosphorylation on Y412 and Y245, two sites
required for full Abl activation, to support growth factor-medi-
ated mitogenic signaling (Dorey et al., 2001; Plattner et al.,
1999). We find that ectopic Mig6/Abl, but not Src/Abl induces
cell death in primary MEFs, raising the possibility that Abl
regulated by RTK/Src show distinct ‘‘mitogenic’’ substrate556 Developmental Cell 23, 547–559, September 11, 2012 ª2012 Elspreference as compared with ‘‘proapoptotic’’ substrates for
Abl regulated by Mig6, hence providing a possible explanation
for the apparent paradox that, depending on the cellular context,
c-Abl can both support growth factor signaling and promote
apoptosis. P73 may be such a specific Mig6/Abl target, given
our observation that Mig6/Abl-induced cell death is prevented
by RNAi silencing of p73. The mechanism by which Mig6/Abl
could regulate p73 activity remains to be clarified; however,
a possibility is that Mig6 is involved in targeting Abl to the
nucleus where Abl has been described to phosphorylate and
activate p73 in response to genotoxic stress (Agami et al.,
1999; Chau et al., 2004; Gong et al., 1999). This is supported
by our observation that c-Abl nuclear localization is impaired in
Errfi1/ primary MECs.
A Physiological Role for c-Abl/Mig6 in Promoting Cell
Death during Epithelial Homeostasis
c-Abl is a multifunctional kinase that is regulated by integrins,
cellular stresses and growth factors. Abl shuttles between
different subcellular compartments including the cytoskeleton,
cytoplasm, nucleus, and plasmamembrane adding another level
of complexity (Hantschel and Superti-Furga, 2004). Elucidating
the biological functions of Abl has proved elusive primarily in
part due to the embryonic or neonatal lethality of c-Abl knockout
mice (Tybulewicz et al., 1991). Previous studies on cell lines
suggest an important role for c-Abl in promoting cell death. Abl
kinase activity is induced by various cellular stresses while loss
of Abl function by RNAi, pharmacological inhibition of kinase
activity and/or genetic deletion (using embryonic fibroblasts
from knockout mice), leads to apoptotic defects in response to
DNA damage, reactive oxygen species, ER stress and the
proapototic cytokine TNFa (Agami et al., 1999; Chau et al.,
2004; Gong et al., 1999; Ito et al., 2001; Noren et al., 2006;
Sun et al., 2000). How Abl is activated by cellular stresses and
how it triggers apoptosis remains largely unclear. Here, we
provide evidence that Mig6-dependent Abl activity is required
for cell death in epithelial cells during mammary ductal homeo-
stasis in response to inactivation of EGFR. Pharmacological
inhibition or RNAi-mediated knockdown of Abl leads to impaired
ductal branching and epithelial cell death with subsequent
luminal filling, either in vivo or in a 3D system of mammary
morphogenesis. Notably, tissue-specific knockdown of Abl
by transplantation of shRNA-targeted pMECs into cleared
mammary fat pads prevented ductal outgrowth, suggesting
that Abl has additional functions required for early mammary
gland outgrowth.
The physiological relevance of ErbB receptor inactivation for
the process of mammary epithelial cell death and lumen forma-
tion is supported by our observation that the luminal cell
compartment that frequently undergoes apoptosis in the interior
of TEBs shows reduced immunoreactivity against active phos-
pho-ErbB2. Furthermore, previous studies have shown that
constitutively active ErbB2 leads to impaired apoptosis and
luminal filling in a 3D model of mammary lumen formation
(Debnath et al., 2002; Muthuswamy et al., 2001). Importantly,
enhanced mitogenic signaling alone induced by oncogenes
(Cyclin D1 or HPV E7) is not sufficient to induce luminal filling
(Debnath et al., 2002), implying a specific requirement for an
ErbB2-derived mitogenic signal.evier Inc.
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sensory mechanism directly links ErbB receptor inactivation to
cell death during epithelial homeostasis independent of canon-
ical mitogenic signaling pathways.
Finally, we and others previously showed that Mig6 is an
important tumor suppressor since knockout mice are highly
susceptible to cancer formation, while Mig6 expression is
frequently lost in various human cancers (Ferby et al., 2006;
Zhang et al., 2007b). Here, we uncover that Mig6 can acts as
a double-edged tumor suppressor that not only attenuates
ErbB-signaling but also directly triggers cells death when ErbB
receptors are inactive. This is of particular interest considering
that acquisition of growth factor-independent survival is likely
to be an early step of cellular transformation (Hanahan and
Weinberg, 2011).
EXPERIMENTAL PROCEDURES
Mouse Lines
Errfi1+/mice were maintained in a mixed Sv129/C57BL/6 background. While
transplantation of lentivirus-infected pMECs were performed in BALB/c mice.
All experiments with mice were performed with approval from the local ethics
committee and the home office.
pMEC Isolation
Mammary glands were harvested from 8- to 12-week-old Errfi1/ and litter-
mate control mice. Lymph nodes were excised and the glands placed into
Leibowitz L15 medium (Invitrogen) containing 10% FCS prior to dissociation
on a McIIwain Tissue Chopper (Mickle). Tissue was digested for 7 hr at 37C
in medium containing 2 mg/ml collagenase (Roche) and 0.02 g/ml hyaluroni-
dase. Erythrocytes were removed with red blood cell lysis buffer (Sigma).
Fibroblasts were removed during a 1 hr incubation in DMEM containing 10%
FCS at 37C. Organoids were sequentially incubated in 5 mg/ml dispase II
for 5 min, Joklik’s MEM, 0.02% w/v EDTA for 10 min, and TrypLE (Invitrogen)
at 37C until a single cell suspension was achieved. 0.1 mg/ml DNase I
(Invitrogen) in L15 containing 10% FCS was added to single cell suspensions
prior to filtering with a 40 mm cell strainer.
Cell Culture and Transfection
pMECs were cultured in mammary epithelial cell basal medium (Promocell),
10 ng/ml EGF, 5 mg/ml insulin, 0.5 mg/ml hydrocortisone, 10 ng/ml Cholera
Toxin, and 2% FCS on tissue culture plates precoated in 1% collagen in
0.02 M acetic acid overnight at 4C. HEK293T and MEFs cells were cultured
in DMEM supplemented with 10% FBS (PAA Laboratories) and transfected
using the CalPhos Transfection kit (Clontech) or Jetprime (Polyplus),
respectively.
Mammary Gland Analysis
Mammary glands were fixed overnight at 4C in 60% w/v methanol, 30% w/v
chloroform, 10% acetic acid. Fixed tissue was stained in carmine aluminum
0.2%w/v carmine red, 0.5%w/v aluminum potassium sulfate for whole-mount
imaging followed by routine procedures for paraffin embedding, sectioning,
and staining with hematoxylin and eosin.
Lentivirus Production and Transduction of pMECs
Standard procedures for lentivirus production and titration were used. Viral
supernatants were concentrated by ultracentrifugation and pMECs were in-
fected for 48 hr prior to in vitro experiments, or overnight on poly-Hema-coated
tissue-culture dishes for cleared fat pad transplantations or 3D Matrigel
cultures.
3D Matrigel Cultures
Lentivirus-infected pMECs (prepared as described above) were plated inside
or on top of Matrigel (BD Biosciences), and cultured in complete mammary
epithelial cell basal medium for 12 days prior to analysis. Notably we onlyDevelopmenobserve branching of wild-type pMEC acini when grown on standard Matrigel
but not growth-factor reduced Matrigel.
Cleared Mammary Fat Pad Transplantation
Wild-type and Errfi1/ pMECs isolated from 12-week-old Sv129/C57BL6
virgin female mice were resuspended in L15 medium (Invitrogen) to a concen-
tration of 50,000 cells in 10 ml L15 medium, followed by injection into cleared
mammary fat pads of 21-day-old Sv129/C57BL6 mice. For transplantation
of Abl shRNA-infected pMECs, cells were isolated from 8-week-old BALB/c
mice, subjected to lentiviral transfection as described above and injected
into the fourth mammary fat pad of 21-day-old BALB/c mice after removal of
endogenous mammary tissue.
Immunofluorescence
Sections (6 mm) were deparaffinized and boiled in 10 mM sodium citrate buffer
and blocked in 5% goat serum and M.O.M. Ig blocking reagent (Invitrogen)
before incubation with primary and fluorofor-conjugated secondary antibodies
(listed in Supplemental Experimental Procedures). After washing in 0.1%
Tween-20 in TBS sections were counterstained with 1 mg/ml DAPI, mounted
and images taken using the Leica TCS SP. Images were modified by intro-
ducing a threshold to eliminate background due to autofluorecence.
Immunoblotting
Cells were either lysed directly in SDS-sample buffer or prepared for coimmu-
noprecipitation (Co-IP) and subjected to SDS-PAGE and western blotting.
Co-IP procedure and list of antibodies used are found in the Supplemental
Experimental Procedures.
c-Abl Tyrosine Kinase Assay
pMEC cell lysates were subjected to immunoprecipitation as described above.
Immunocomplexes were incubated at 30C for 20min in kinase reaction buffer
containing 20 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 10% v/v glycerol, 1 mM
DTT, 1.5 mg/10 ml Abltide (Millipore) peptide substrate, and 5 mC/10 ml reaction
32P-g-ATP.
Trypan Blue Exclusion Assay
pMECs from Errfi1/ or wild-type 8- to 12-week-old mice were cultured to
70%–90% subconfluency prior to 8 hr EGF deprivation. Cells were treated
with 0.2% trypan blue (Invitrogen) for 3 min followed by determination of the
ratio of blue cells over total number of cells by transmission microscopy.
EGF Deprivation Assay
pMECs were grown for 3–7 days to 70%–90% subconfluency prior to substi-
tution to either EGF-supplemented or EGF-deficient complete media and
cultured for indicated times in the absence or presence of the inhibitors;
1 mM gefitinib, 1 mM lapatinib, and 1 mM nilotinib (LC Laboratories) or 1 mM
AG825, 1 mM c-Met inhibitor II, or 10 mM SU6656 (Merck).
In Vivo Nilotinib Treatment and BrdU Incorporation
Errfi1/ and littermate control mice were injected intraperitoneally with
75 mg/g nilotinib 1:1 v/v in polyethylene glycol-200 daily for 7 days and with
0.25 mg/g BrdU in PBS 2 hr prior to sacrifice.
Anoikis and DNA Damage Assays
pMECs were resuspended in methyl cellulose and cultured on culture dishes
precoated with 20 mg/ml polyhema. pMECs were cultured in mammary
epithelial cell medium containing 1 mg/ml adriamycin for 24 hr before harvest-
ing for protein.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.devcel.2012.08.001.
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